{"disease":{"id":"primary-invasive-breast-cancer","name":"primary invasive breast cancer"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04622319","title":"A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1600,"lead_sponsor_name":"Daiichi Sankyo","has_results":false},{"nct_id":"NCT03503799","title":"Reaching for Evidence-baSed Chemotherapy Use in Endocrine Sensitive Breast Cancer","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1191,"lead_sponsor_name":"North Eastern German Society of Gynaecological Oncology","has_results":false},{"nct_id":"NCT04016935","title":"EndoPredict® Extended Endocrine Trial (EXET)","phase":"","overall_status":"TERMINATED","enrollment_count":855,"lead_sponsor_name":"Myriad Genetic Laboratories, Inc.","has_results":false},{"nct_id":"NCT03113825","title":"Study of AVB-620 in Women With Primary, Nonrecurrent Breast Cancer Undergoing Surgery","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":92,"lead_sponsor_name":"Avelas Biosciences, Inc.","has_results":false}],"total":4},"guidelines":[],"source":"Drug Landscape verified database"}